Mechanisms of KRAS Inhibitor Resistance Revealed

Abstract A recent study revealed diverse mechanisms of acquired resistance in patients with non–small cell lung cancer or colorectal cancer who stop responding to a KRASG12C inhibitor. These patients developed secondary KRAS mutations, MAPK pathway alterations, or genomic rearrangements—and in some cases multiple resistance mechanisms occurred simultaneously.